1.11 -0.02 (-1.77%) | 01-19 00:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.95 | 1-year : | 2.38 |
Resists | First : | 1.67 | Second : | 2.03 |
Pivot price | 1.49 | |||
Supports | First : | 1.09 | Second : | 0.9 |
MAs | MA(5) : | 1.11 | MA(20) : | 1.55 |
MA(100) : | 1.34 | MA(250) : | 2.36 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 2.1 | D(3) : | 2.1 |
RSI | RSI(14): 41.6 | |||
52-week | High : | 4.84 | Low : | 0.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OSMT ] has closed above bottom band by 20.4%. Bollinger Bands are 190.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Wed, 30 Mar 2022
RVL Pharmaceuticals Stock: A Makeover For An Ugly Duckling - Seeking Alpha
Wed, 19 Jan 2022
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New ... - GlobeNewswire
Fri, 25 Jun 2021
Osmotica Stock Surges On $170M Divestiture Deal With Alora Pharmaceuticals - Yahoo Finance
Tue, 28 Jul 2020
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan ... - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 83 (M) |
Shares Float | 32 (M) |
Held by Insiders | 31 (%) |
Held by Institutions | 35.2 (%) |
Shares Short | 412 (K) |
Shares Short P.Month | 130 (K) |
EPS | -1.6 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.87 |
Profit Margin | -60.4 % |
Operating Margin | -8.5 % |
Return on Assets (ttm) | -3.3 % |
Return on Equity (ttm) | -102.8 % |
Qtrly Rev. Growth | -91.5 % |
Gross Profit (p.s.) | 1.24 |
Sales Per Share | 1.99 |
EBITDA (p.s.) | -0.04 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -39 (M) |
Levered Free Cash Flow | 16 (M) |
PE Ratio | -0.7 |
PEG Ratio | 0 |
Price to Book value | 1.27 |
Price to Sales | 0.55 |
Price to Cash Flow | -2.4 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |